electroCore, Inc. Launches New Wellness Product Offering for Stress, Anxiety and Sleep, Truvaga™
December 20 2022 - 8:00AM
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
company, today announced the launch of a new wellness product
offering called TruvagaTM for customers residing in the United
States. The new wellness product is offered through our new
ecommerce site, www.truvaga.com, and promotes general
wellbeing.
Truvaga is a handheld non-invasive vagus nerve stimulator that
utilizes our proven technology to quickly and gently activate the
vagus nerve. Stress affects every aspect of our lives including
sleep, memory, learning, weight, fitness and more. Truvaga offers a
drug-free, simple, and convenient way to help reduce stress with
just 2-minute sessions, day and night; no apps, batteries, chargers
or phones are required.
“The launch of a wellness product is a tremendous step forward
in our company’s strategy of making vagus nerve stimulation
technology more accessible to people who can benefit from
harnessing the power of the vagus nerve,” stated Dan Goldberger,
Chief Executive Officer at electroCore. “The Truvaga product will
allow customers to incorporate vagus nerve stimulation as part of a
holistic approach to improving their wellbeing.”
About electroCore, Inc.electroCore, Inc. is a
commercial stage bioelectronic company dedicated to improving
outcomes through its non-invasive vagus nerve stimulation therapy
platform. The Company is focused on the treatment of multiple
conditions in neurology and product offerings promoting general
wellbeing and human performance.
For more information, visit www.electrocore.com.
About TruvagaTMTruvaga is a handheld vagus
nerve stimulator that utilizes our proven technology to quickly and
gently activate the vagus nerve. It’s designed to work with the
body to balance the nervous system to feel calmer, think
clearer, and sleep better.
For more information, please visit www.truvaga.com.
Forward-Looking StatementsThis press release
and other written and oral statements made by representatives of
electroCore may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements include, but are not limited to,
statements about electroCore's business prospects, wellness product
offerings, new ecommerce site, and clinical and product development
plans; its pipeline or potential markets for its technologies; the
timing, outcome and impact of regulatory, clinical and commercial
developments; the Company’s business prospects in the United States
(including its e-commerce initiatives) and other new markets and
other statements that are not historical in nature, particularly
those that utilize terminology such as "anticipates," "will,"
"expects," "believes," "intends," other words of similar meaning,
derivations of such words and the use of future dates. Actual
results could differ from those projected in any forward-looking
statements due to numerous factors. Such factors include, among
others, the ability to raise the additional funding needed to
continue to pursue electroCore’s business and product development
plans, the inherent uncertainties associated with developing new
products or technologies, the ability to commercialize gammaCore™,
the potential impact and effects of COVID-19 on the business of
electroCore, electroCore’s results of operations and financial
performance, and any measures electroCore has and may take in
response to COVID-19 and any expectations electroCore may have with
respect thereto, competition in the industry in which electroCore
operates and overall market conditions. Any forward-looking
statements are made as of the date of this press release, and
electroCore assumes no obligation to update the forward-looking
statements or to update the reasons why actual results could differ
from those projected in the forward-looking statements, except as
required by law. Investors should consult all of the information
set forth herein and should also refer to the risk factor
disclosure set forth in the reports and other documents electroCore
files with the SEC available at www.sec.gov.
Investors:Rich CockrellCG
Capital404-736-3838ecor@cg.capital
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Jul 2024 to Jul 2024
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Jul 2023 to Jul 2024